Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found that VIP-SSL (0.1 nmol) administered by either routes normalizes MAP (p < 0.05). Maximal effect was observed within 10-20 min and lasted for 6 h. VIP-SSL had no significant effects on heart rate. VIP alone (0.1 nmol) and empty SSL had no significant effects on MAP. VIP-SSL (0.1 nmol) had no significant effects on MAP and heart rate in age/genetically-matched control hamsters. Given these data, we suggest that pulmonary and subcutaneous delivery of VIP-SSL should be further developed as peptide nanomedicine for essential hypertension.
Department of Medicine (M/C 719), University of Illinois at Chicago, 840 South Wood Street, Chicago, IL 60612-7323, USA. IRubinst@uic.edu
Israel
I
Rubinstein
Hiroyuki
H
Ikezaki
Hayat
H
Onyüksel
D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D006224:Cricetinae; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007279:Injections, Subcutaneous; D007442:Intubation, Intratracheal; D008081:Liposomes; D008297:Male; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000959:Antihypertensive Agents; D008081:Liposomes; D014660:Vasoactive Intestinal Peptide